Long-Term Follow-Up of Patients with CML Continuing to Receive Omacetaxine Mepesuccinate in 2 Phase II Trials


Long-Term Follow-Up of Patients with CML Continuing to Receive Omacetaxine Mepesuccinate in 2 Phase II Trials
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Hagop M Kantarjian, MD (2/20/13)

Kantarjian HM et al. Long-term follow-up of ongoing patients in 2 studies of omacetaxine mepesuccinate for chronic myeloid leukemia. Proc ASH 2012;Abstract 2787.

Dr Kantarjian is Chairman and Professor of the Leukemia Department at The University of Texas MD Anderson Cancer Center in Houston, Texas.